早产或小于胎龄儿宏量营养素补充对发育与代谢结局的影响:系统综述与Meta分析
该系统综述与Meta分析纳入21项随机试验和1项准随机试验共3680名出生时偏小(早产或小于胎龄)的婴儿,评估宏量营养素补充对出院后认知与代谢结局的影响。补充未改变幼儿期认知损害风险,但减少了运动损害;儿童期补充组空腹血糖更低、高密度脂蛋白更高。证据质量低至极低且存在异质性。
要点
- 幼儿期补充组与未补充组认知损害风险无差异(RR 1.00,95%CI 0.67–1.49,P=0.99)。
- 幼儿期补充组运动损害少于未补充组(RR 0.76,95%CI 0.62–0.94,P=0.01)。
- 儿童期补充组空腹血糖低于未补充组(MD -0.20 mmol/L,95%CI -0.34至-0.06,P=0.005)。
核心结论
- 在随机试验的系统综述与Meta分析中,未发现出生偏小婴儿早期宏量营养素补充改变远期认知功能的证据,但有一定证据提示补充可能减少幼儿期运动损害。
- 与观察性研究结果相反,随机试验证据提示出生偏小婴儿早期宏量营养素补充改善了儿童期部分代谢结局。
研究设计与样本
- 系统综述与Meta分析,检索OvidMedline、Embase、Cochrane CENTRAL和Cochrane Database of Systematic Reviews自建库至2019年4月1日,以及controlled-trials.com、clinicaltrials.gov和anzctr.org.au。
- 纳入旨在增加宏量营养素摄入以改善出生偏小婴儿生长或发育并评估出院后结局的随机或准随机试验。
- 共纳入21项随机试验和1项准随机试验,涉及3680名婴儿,方法学质量不一。
- 采用Cochrane偏倚风险工具评估质量,使用随机效应模型合并数据;PROSPERO注册号CRD42019127858。
主要发现
- 幼儿期(<3岁)出生偏小婴儿中,补充组与未补充组认知损害无差异(RR 1.00,95%CI 0.67–1.49,P=0.99),认知评分无差异(MD 0.57,95%CI -0.71–1.84,P=0.38),运动评分无差异(MD 1.16,95%CI -0.32–2.65,P=0.12),但补充组运动损害更少(RR 0.76,95%CI 0.62–0.94,P=0.01)。
- 亚组分析中,补充改善了出生偏小男童的认知评分(MD 5.60,95%CI 1.07–10.14,P=0.02),但未改善女童认知评分(MD -2.04,95%CI -7.04–2.95,P=0.42);在小于胎龄儿亚组中补充未改变认知或运动评分。
- 儿童期(3–8岁)补充组与未补充组认知损害无差异(RR 0.81,95%CI 0.26–2.57,P=0.72),认知评分无差异(MD 1.02,95%CI -1.91–3.95,P=0.50),血压、甘油三酯和低密度脂蛋白浓度均无差异(均P>0.05)。
- 儿童期补充组空腹血糖低于未补充组(MD -0.20 mmol/L,95%CI -0.34至-0.06,P=0.005),高密度脂蛋白浓度高于未补充组(MD 0.11 mmol/L,95%CI 0.02–0.19,P=0.02)。
- 青春期(9–18岁)补充组与未补充组在血压、甘油三酯、低密度脂蛋白和高密度脂蛋白浓度、空腹血糖、胰岛素抵抗及空腹胰岛素浓度方面均无差异(均P>0.05)。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 存在相当大的无法解释的异质性。
- 证据质量低至极低。
- 超出儿童早期的数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nutritional supplements may improve development of infants born small (preterm or small for gestational age [SGA]) but may increase the risk of later metabolic disease. We conducted a systematic review and meta-analysis to assess the effects of macronutrient supplements for infants born small on later development and metabolism. METHODS AND FINDINGS: We searched OvidMedline, Embase, Cochrane CENTRAL, and Cochrane Database of Systematic Reviews from inception to April 1, 2019, and controlled-trials.com, clinicaltrials.gov, and anzctr.org.au. Randomised or quasirandomised trials were included if the intention was to increase macronutrient intake to improve growth or development of infants born small and assessed post-discharge outcomes. Co-primary outcomes were cognitive impairment and metabolic risk, evaluated in toddlers (<3 years), childhood (3 to 8 years), and adolescence (9 to 18 years). Two reviewers independently extracted data. Quality was assessed using the Cochrane Risk of Bias tool, and data were pooled using random-effect models. Twenty-one randomised and one quasirandomised trial of variable methodological quality involving 3,680 infants were included. In toddlers born small, supplementation did not alter cognitive impairment (relative risk [RR] 1.00; 95% confidence interval [CI] 0.67 to 1.49; P = 0.99), and there were no differences in cognitive scores (mean difference [MD] 0.57; 95% CI -0.71 to 1.84; P = 0.38) or motor scores (MD 1.16; 95% CI -0.32 to 2.65; P = 0.12) between supplemented and unsupplemented groups. However, fewer supplemented children had motor impairment (RR 0.76; 95% CI 0.62 to 0.94; P = 0.01). In subgroup analyses, supplementation improved cognitive scores in boys (MD 5.60; 95% CI 1.07 to 10.14; P = 0.02), but not girls born small (MD -2.04; 95% CI -7.04 to 2.95; P = 0.42), and did not alter cognitive or motor scores in the subgroup of children born SGA. In childhood, there was no difference in cognitive impairment (RR 0.81; 95% CI 0.26 to 2.57; P = 0.72) or cognitive scores (MD 1.02; 95% CI -1.91 to 3.95; P = 0.50) between supplemented and unsupplemented groups. There were also no differences in blood pressure, triglyceride, and low-density lipoprotein (LDL) concentrations (all P > 0.05). However, supplemented children had lower fasting glucose (mmol/L: MD -0.20; 95% CI -0.34 to -0.06; P = 0.005) and higher high-density lipoprotein (HDL) concentrations (mmol/L: MD 0.11; 95% CI 0.02 to 0.19; P = 0.02). In subgroup analyses, there was no evidence of differences in blood pressure between supplemented and unsupplemented groups in boys or girls born small, or in SGA children. In adolescence, there was no difference between supplemented and unsupplemented groups in blood pressure, triglycerides, LDL and HDL concentrations, fasting blood glucose, insulin resistance, and fasting insulin concentrations (all P > 0.05). Limitations include considerable unexplained heterogeneity, low to very low quality of the evidence, and limited data beyond early childhood. CONCLUSIONS: In this systematic review and meta-analysis of randomised trials, we found no evidence that early macronutrient supplementation for infants born small altered later cognitive function, although there was some evidence that supplementation may decrease motor impairment in toddlers. Contrary to the findings from observational studies, evidence from randomised trials suggests that early macronutrient supplementation for infants born small improves some metabolic outcomes in childhood. PROSPERO REGISTRATION: CRD42019127858.
引用
- Lin L, Amissah E, Gamble GD, et al. Impact of macronutrient supplements for children born preterm or small for gestational age on developmental and metabolic outcomes: A systematic review and meta-analysis. PLoS Med. 2019. PMID: 31665140. doi:10.1371/journal.pmed.1002952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。